High content screening to identify therapeutics for multiple sclerosis

高内涵筛查以确定多发性硬化症的治疗方法

• 批准号: 8543776
• 负责人: Chunyang Brian Bai
• 金额: $ 29.84万
• 依托单位: RENOVO NEURAL, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-15 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8543776
• 关键词: Affect; Agonist; Algorithms; Anti-Inflammatory Agents; Anti-inflammatory; Axon; Biological; Blood Chemical Analysis; Brain; Cardiac; Cell Differentiation process; Cell Line; Cell Maturation; Cells; Chemical Structure; Chronic; Cuprizone; Cytochrome P450; Demyelinations; Development; Disease; Dose; Embryo; Encapsulated; Etiology; Evaluation; Female; Fibroblast Growth Factor 2; Future; Generations; Goals; Human; Immune; In Vitro; Individual; Infiltration; Inflammation; Inflammatory; Lead; Legal patent; Lesion; Libraries; Methods; Modeling; Multiple Sclerosis; Multiple Sclerosis Lesions; Mus; Myelin; Myelin Sheath; Nervous System Physiology; Nervous system structure; Neurologic; North America; Oligodendroglia; Pathologic; Pathway interactions; Patients; Phase; Platelet-Derived Growth Factor; Population; Production; Rattus; Reader; Recovery of Function; Signal Pathway; Staging; Stem cells; Structure-Activity Relationship; Testing; Therapeutic; Therapeutic Agents; Therapeutic Intervention; Toxicity Tests; Undifferentiated; analog; axonal degeneration; base; cell type; central nervous system demyelinating disorder; cytotoxicity; disability; drug candidate; in vivo; innovation; male; mouse model; nervous system disorder; phase 2 study; relating to nervous system; remyelination; repaired; research study; response; screening; small molecule; small molecule libraries; success; technological innovation; young adult

DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the central nervous system (CNS) and is the major cause of non-traumatic neurological disability in young adults in North America. Although the etiology of MS is not clear, its onset is characterized by infiltration of immune cells and the destruction of oligodendrocytes and myelin. After 5-15 years, most patients enter a phase of axonal degeneration and gradual, irreversible neurological decline. There is no cure for MS. Current anti- inflammatory or immunomodulatory therapies are partially effective in delaying the disease, but these therapies do not guarantee functional recovery. Replacement of oligodendrocytes and their subsequent remyelination of demyelinated axons could halt and reverse axonal loss and neurological decline. One approach to increase remyelination is through therapeutic stimulation of endogenous repair. This approach is feasible since generation of new oligodendrocytes and spontaneous remyelination do occur in many MS lesions during early stages of the disease, and even in some chronic lesions, although endogenous remyelination eventually fails. The hypothesis of this proposal is that selected small molecules can be used as remyelination therapeutics to stimulate differentiation of oligodendrocytes and remyelination. Two recent technological developments enable the identification and evaluation of such small molecules. First, an optimized method to produce a highly pure population of primary oligodendrocyte progenitor cells (OPCs) from the mouse that can be used as starting material for screening. Second, a high-content, cell-based phenotypic screening method to automatically score differentiated oligodendrocytes in a medium-throughput manner. This innovative platform will be used to screen a small molecule library to identify hits that can promote OPC differentiation. Putative hits from the primary screen will then be evaluated for their ability to activate the expression of oligodendrocyte-specific markers. Potency, cytotoxicity, cell-type selectivity and interaction with known signaling pathways that regulate oligodendrocyte generation will also be evaluated. The goal of this Phase I project is to identify the best small molecule drug candidate that can promote differentiation of OPCs for subsequent Phase II studies and development. Future Phase II projects will include detailed toxicological studies of the lead compound and in vivo testing in the mouse cuprizone model of demyelination. The long-term goal of this project is to develop therapeutic agents that will promote remyelination to reverse neurological decline in MS patients.

描述（由申请人提供）：多发性硬化症（MS）是中枢神经系统（CNS）最常见的炎性脱髓鞘疾病，是北美年轻人非创伤性神经功能障碍的主要原因。虽然MS的病因尚不清楚，但其发病的特征是免疫细胞的浸润以及少突胶质细胞和髓鞘的破坏。5-15年后，大多数患者进入轴突变性和逐渐的、不可逆的神经功能衰退阶段。目前还没有治愈MS的方法。目前的抗炎或免疫调节疗法在延迟疾病方面部分有效，但这些疗法不能保证功能恢复。少突胶质细胞的替代及其随后的脱髓鞘轴突的髓鞘再生可以阻止和逆转轴突丢失和神经功能衰退。增加髓鞘再生的一种方法是通过内源性修复的治疗性刺激。这种方法是可行的，因为新的少突胶质细胞和自发髓鞘再生的产生确实发生在疾病的早期阶段的许多MS病变，甚至在一些慢性病变，虽然内源性髓鞘再生最终失败。该提议的假设是，选择的小分子可以用作髓鞘再生治疗剂以刺激少突胶质细胞的分化和髓鞘再生。最近的两项技术发展使这种小分子的鉴定和评价成为可能。首先，优化的方法，以产生高纯度的原代少突胶质细胞祖细胞（OPC）从小鼠，可以用作筛选的起始材料的群体。第二，高含量的，基于细胞的表型筛选方法，以中等通量的方式自动评分分化的少突胶质细胞。这个创新平台将用于筛选小分子文库，以识别可以促进OPC分化的命中。主屏幕上的假定命中将 评估它们激活少突胶质细胞特异性标志物表达的能力。还将评价效价、细胞毒性、细胞类型选择性以及与调节少突胶质细胞生成的已知信号传导途径的相互作用。该I期项目的目标是确定可以促进OPCs分化的最佳小分子候选药物，用于随后的II期研究和开发。未来的第二阶段项目将包括铅化合物的详细毒理学研究和脱髓鞘的小鼠cuprizone模型的体内测试。该项目的长期目标是开发促进髓鞘再生的治疗药物，以逆转MS患者的神经功能衰退。